ArticleBlood advances2026
Single-cell long-read genotyping of transcripts reveals discrete mechanisms of clonal evolution in post-MPN AML.
Article in Blood advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- LOTR-Seq: A protocol for large-scale simultaneous single-cell long-read genotyping of transcripts.STAR protocols · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
abstractMyeloproliferative neoplasms (MPNs) are caused by acquired mutations in hematopoietic stem and progenitor cells (HSPCs). The acquisition of additional mutations, such as TP53, and the overall mutational burden influence a patient's risk of disease progression to lethal post-MPN acute myeloid leukemias (AML). Recent technological advancements in linking single-cell gene expression with genotype have improved our understanding of tumor heterogeneity. However, current methodologies have limitations in simultaneously genotyping low-expression genes (such as JAK2) alongside other pathogenic loci. To address this, we developed a novel long-read genotyping pipeline of complementary DNA transcripts (long-read genotyping of transcripts [LOTR]-Seq), which can genotype the full length of expressed transcripts from 30 genes at once. Using LOTR-Seq, we genotyped HSPCs at the JAK2V617 locus in 9075 single cells from 8 patients with chronic-phase MPN (CP-MPN) and in 5016 cells from 4 patients with post-MPN AML. We then linked the mutations to the single-cell transcriptomes of 29 712 JAK2V617F-driven CP-MPN cells and 16 895 post-MPN AML cells. In our analysis of post-MPN AML, we identified 9 mutated loci across 6 genes (JAK2, IDH1/2, TP53, SRSF2, and U2AF1) and linked these mutations to specific transcriptional phenotypes. Overall, LOTR-Seq provides novel insights into the evolution of post-MPN AML.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.